STOCKHOLM--(BUSINESS WIRE)--GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer’s disease-associated beta amyloid brain pathology.1 [18F]Flutemetamol is a PET imaging agent being developed by GE Healthcare for the detection of beta amyloid deposits in the brain. The data from the phase III studies further confirm the potential application of [18F]flutemetamol as an imaging agent to detect beta amyloid plaques.
